Literature DB >> 17536106

Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer.

Daria Handkiewicz-Junak1, Jan Wloch, Jozef Roskosz, Jolanta Krajewska, Aleksandra Kropinska, Lech Pomorski, Aleksandra Kukulska, Andrzej Prokurat, Zbigniew Wygoda, Barbara Jarzab.   

Abstract

UNLABELLED: We sought to assess whether extensive surgical treatment, postsurgical radioiodine therapy, or both decrease the risk of locoregional recurrence (LR) after curative primary treatment in children and adolescents diagnosed with differentiated thyroid cancer (DTC) at age <or=18 y.
METHODS: To determine the incidence of and identify predictive factors for thyroid bed recurrence (TBR) or lymph node recurrence (NR), we performed a chart review and retrospective multivariate Cox regression analysis on 235 patients with DTC diagnosed at age <or=18 y and managed with curative intent at our tertiary referral center from 1973 to 2002; 40 of these patients had distant metastases at diagnosis. We also determined overall and recurrence-free survival and generated curves for these variables using Kaplan-Meier and Cox univariate analysis.
RESULTS: During a median follow-up of 82 mo (range, 5-402 mo), no DTC-related deaths occurred, 203 (86%) children remained recurrence-free, and 32 (14%) children had LR, including TBR in 9 (28% of LR), NR in 20 (63% of LR), and both in 3 (9% of LR). Among patients treated with radical intent and showing no distant metastases, the most recent thyroglobulin level was <1 ng/mL in all but 4% of cases. The median time from the first surgery to LR was 37 mo (range, 9-280 mo). In multivariate analysis, significant risk factors for TBR were less than total thyroidectomy and lack of postsurgical radioiodine treatment (respective risk increases of 9.5 [P = 0.04] and 11 times [P = 0.03]). For NR, classic papillary histology, incomplete primary lymph node management (i.e., lack of modified lymphadenectomy of affected lymph nodes or lack of confirmation of disease-free nodes by intraoperative staging), and absence of adjuvant radioiodine therapy were independent significant predictive factors that increased the recurrence risk by 1.9 (P = 0.02), 3.3 (P = 0.02), and 3.2 (P = 0.02) times, respectively. Age or sex did not correlate with LR risk.
CONCLUSION: In DTC patients <or=18 y of age, extensive initial therapy-consisting of total thyroidectomy combined with modified lymphadenectomy performed in case of lymph node metastases and followed by radioiodine therapy--is associated with a substantial decrease of DTC LR risk.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17536106     DOI: 10.2967/jnumed.106.035535

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  42 in total

1.  Pediatric thyroid cancers: an Indian perspective.

Authors:  Devendra A Chaukar; Abhishek D Vaidya
Journal:  Indian J Surg Oncol       Date:  2012-02-16

Review 2.  Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Gary L Francis; Steven G Waguespack; Andrew J Bauer; Peter Angelos; Salvatore Benvenga; Janete M Cerutti; Catherine A Dinauer; Jill Hamilton; Ian D Hay; Markus Luster; Marguerite T Parisi; Marianna Rachmiel; Geoffrey B Thompson; Shunichi Yamashita
Journal:  Thyroid       Date:  2015-07       Impact factor: 6.568

3.  Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons.

Authors:  Hiroshi Takami; Yasuhiro Ito; Takahiro Okamoto; Akira Yoshida
Journal:  World J Surg       Date:  2011-01       Impact factor: 3.352

Review 4.  The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy.

Authors:  Scott A Rivkees; Ernest L Mazzaferri; Frederik A Verburg; Christoph Reiners; Markus Luster; Christopher K Breuer; Catherine A Dinauer; Robert Udelsman
Journal:  Endocr Rev       Date:  2011-08-31       Impact factor: 19.871

5.  Papillary thyroid carcinoma does not have standard course in children.

Authors:  Ibrahim Karnak; Burak Ardıçlı; Saniye Ekinci; Arbay Ozden Ciftçi; Diclehan Orhan; Gülsev Kale; Feridun Cahit Tanyel; Mehmet Emin Senocak
Journal:  Pediatr Surg Int       Date:  2011-05-24       Impact factor: 1.827

6.  Papillary Thyroid Carcinoma in Children: Clinicopathological Profile and Outcomes of Management.

Authors:  John K Thomas; Jujju Jacob Kurian; Anish Jacob Cherian; Julie Hephzibah; M J Paul; Deepak Thomas Abraham
Journal:  World J Surg       Date:  2020-10-19       Impact factor: 3.352

7.  Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008.

Authors:  Ian D Hay; Tomas Gonzalez-Losada; Megan S Reinalda; Jennifer A Honetschlager; Melanie L Richards; Geoffrey B Thompson
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

8.  Differentiated thyroid carcinoma: comparison of histopathologic characteristics, clinical course, and outcome between young children and adolescents.

Authors:  M Motazedian; B Shafiei; P Vatankhah; S Hoseinzadeh; M Mirzababaee; L Fathollahi; M Ansari; N Baharfar; F Tabeie; I Neshandar Asli
Journal:  Med Oncol       Date:  2013-02-20       Impact factor: 3.064

9.  Five months' follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by (131)I-SPECT/CT at the first radioablation.

Authors:  Daniela Schmidt; Rainer Linke; Michael Uder; Torsten Kuwert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-20       Impact factor: 9.236

10.  13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study.

Authors:  Daria Handkiewicz-Junak; Jozef Roskosz; Kornelia Hasse-Lazar; Sylwia Szpak-Ulczok; Zbigniew Puch; Aleksandra Kukulska; Tomasz Olczyk; Andrzej Piela; Ewa Paliczka-Cieslik; Barbara Jarzab
Journal:  Thyroid Res       Date:  2009-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.